COMparison Between Anakinra and Tocilizumab in NORSE - "COMBAT-NORSE"

Inclusion Criteria

• •Age 2 and older.
• •In their usual state of health prior to their onset of SE.
• •Presenting with NORSE as defined in the consensus criteria:
• •1. Refractory SE (failed 2 appropriately used anti-seizure medications) in a patient without active epilepsy or other pre-existing relevant neurological disorder and without an acute or active structural, toxic, or metabolic cause found in the first 72 hours.
• •2. Includes patients with any RSE, not just super-refractory SE.
• •3. Includes patients who ultimately are discovered to have a known etiology (infectious, autoimmune, genetic, etc.), as well as those who remain cryptogenic.
• •Anakinra and/or tocilizumab are being planned or considered as part of standard clinical care.
• •The onset of SE was in the prior 7 days at the time of enrollment.